Overview

Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC

Status:
NOT_YET_RECRUITING

Trial end date:
2028-06-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, open-label study to evaluate the preliminary efficacy of SKB264 and the effect of clarithromycin on the PK of SKB264 in patients with ovarian epithelial cancer.

Phase:

PHASE2

Details

Lead Sponsor:

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Treatments:

Clarithromycin